{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T17:17:00Z","timestamp":1788283020514,"version":"build-2803163510"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ajo.2026.06.035","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T06:13:14Z","timestamp":1782108794000},"page":"192-203","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Therapeutic Response to Anti-Vascular Endothelial Growth Factor Retreatment Among Eyes With Stabilized Vision After Being Lost to Follow-Up in Diabetic Macular Edema: A Nationwide, Registry-Based Cohort Study"],"prefix":"10.1016","volume":"290","author":[{"given":"Chuandi","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinchen","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaorong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yupeng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenfang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suyan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5414-593X","authenticated-orcid":false,"given":"Hongbin","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honghua","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5869-7312","authenticated-orcid":false,"given":"Zongming","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianzi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuhui","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tongtong","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongdi","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhipeng","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanping","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningyao","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongqing","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0115-7160","authenticated-orcid":false,"given":"Kun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ajo.2026.06.035_bib0001","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ophtha.2018.07.027","article-title":"Outcomes of eyes lost to follow-up with proliferative diabetic retinopathy that received panretinal photocoagulation versus intravitreal anti-vascular endothelial growth factor","volume":"126","author":"Obeid","year":"2019","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1016\/j.ajo.2026.06.035_bib0002","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.ophtha.2018.02.034","article-title":"Loss to follow-up in patients with proliferative diabetic retinopathy after panretinal photocoagulation or intravitreal anti-VEGF injections","volume":"125","author":"Obeid","year":"2018","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1016\/j.ajo.2026.06.035_bib0003","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1016\/j.ophtha.2014.07.020","article-title":"Gaps in receipt of regular eye examinations among Medicare beneficiaries diagnosed with diabetes or chronic eye diseases","volume":"121","author":"Sloan","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2026.06.035_bib0004","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ajo.2020.03.023","article-title":"Predictors of lost to follow-up in patients being treated for proliferative diabetic retinopathy","volume":"216","author":"Green","year":"2020","journal-title":"Am J Ophthalmol"},{"issue":"10","key":"10.1016\/j.ajo.2026.06.035_bib0005","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.4103\/ijo.IJO_1866_19","article-title":"Factors affecting compliance to intravitreal anti-vascular endothelial growth factor therapy in Indian patients with retinal vein occlusion, age-related macular degeneration, and diabetic macular edema","volume":"68","author":"Kelkar","year":"2020","journal-title":"Indian J Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajo.2026.06.035_bib0006","article-title":"Visual\/anatomical outcome of diabetic macular edema patients lost to follow-up for more than 1 year","volume":"11","author":"Kim","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.ajo.2026.06.035_bib0007","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ajo.2019.03.005","article-title":"Anti-vascular endothelial growth factor therapy for diabetic retinopathy: consequences of inadvertent treatment interruptions","volume":"204","author":"Wubben","year":"2019","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ajo.2026.06.035_bib0008","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ajo.2021.06.028","article-title":"Outcomes of eyes with diabetic macular edema that are lost to follow-up after anti-vascular endothelial growth factor therapy","volume":"233","author":"Matsunaga","year":"2022","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ajo.2026.06.035_bib0009","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ajo.2020.06.040","article-title":"The short-term effect of a single lapse in anti-vascular endothelial growth factor treatment for diabetic macular edema within routine clinical practice","volume":"219","author":"Yalamanchili","year":"2020","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajo.2026.06.035_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.xops.2026.101107","article-title":"Persistent vision loss of eyes lost to follow-up with diabetic macular edema receiving intravitreal anti-VEGF therapy","volume":"6","author":"Zhou","year":"2026","journal-title":"Ophthalmol Sci"},{"key":"10.1016\/j.ajo.2026.06.035_bib0011","doi-asserted-by":"crossref","DOI":"10.7189\/jogh.13.04126","article-title":"Visual impairment and blindness caused by retinal diseases: a nationwide register-based study","volume":"13","author":"Zhou","year":"2023","journal-title":"J Glob Health"},{"issue":"19","key":"10.1016\/j.ajo.2026.06.035_bib0012","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1001\/jama.2019.5790","article-title":"Effect of initial management with aflibercept vs laser photocoagulation vs observation on vision loss among patients with diabetic macular edema involving the center of the macula and good visual acuity: a randomized clinical trial","volume":"321","author":"Baker","year":"2019","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.ajo.2026.06.035_bib0013","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1016\/j.ophtha.2012.08.022","article-title":"Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results","volume":"119","author":"Elman","year":"2012","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1016\/j.ajo.2026.06.035_bib0014","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/j.ophtha.2015.02.036","article-title":"Predictors of functional and anatomic outcomes in patients with diabetic macular edema treated with ranibizumab","volume":"122","author":"Sophie","year":"2015","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.ajo.2026.06.035_bib0015","doi-asserted-by":"crossref","first-page":"e421","DOI":"10.1111\/aos.14308","article-title":"Serum pro-inflammatory factors as predictors of persistent diabetic macular oedema with limited anatomic response to anti-VEGF: association with intravitreal injection treatment profiles in real-world setting","volume":"98","author":"Brito","year":"2020","journal-title":"Acta Ophthalmol"},{"issue":"8","key":"10.1016\/j.ajo.2026.06.035_bib0016","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1056\/NEJMoa2204225","article-title":"Aflibercept monotherapy or bevacizumab first for diabetic macular edema","volume":"387","author":"Jhaveri","year":"2022","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ajo.2026.06.035_bib0017","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s00417-021-05369-9","article-title":"Efficacy and safety of single-dose dexamethasone implantation for patients with persistent diabetic macular edema: a systematic review and meta-analysis","volume":"260","author":"Yuan","year":"2022","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"7","key":"10.1016\/j.ajo.2026.06.035_bib0018","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1136\/bjophthalmol-2018-312244","article-title":"Intravitreal injection of a Rho-kinase inhibitor (fasudil) combined with bevacizumab versus bevacizumab monotherapy for diabetic macular oedema: a pilot randomised clinical trial","volume":"103","author":"Ahmadieh","year":"2019","journal-title":"Br J Ophthalmol"},{"issue":"11","key":"10.1016\/j.ajo.2026.06.035_bib0019","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1007\/s00417-019-04383-2","article-title":"Combination of intravitreal bevacizumab and erythropoietin versus intravitreal bevacizumab alone for refractory diabetic macular edema: a randomized double-blind clinical trial","volume":"257","author":"Entezari","year":"2019","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ajo.2026.06.035_bib0020","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2147\/OPTH.S75842","article-title":"Targeted photocoagulation of peripheral ischemia to treat rebound edema","volume":"9","author":"Singer","year":"2015","journal-title":"Clin Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajo.2026.06.035_bib0021","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1136\/bjo.2004.051540","article-title":"Subthreshold diode micropulse photocoagulation for the treatment of clinically significant diabetic macular oedema","volume":"89","author":"Luttrull","year":"2005","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2026.06.035_bib0022","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.jcjo.2013.11.012","article-title":"Vitrectomy for diabetic macular edema: a systematic review and meta-analysis","volume":"49","author":"Simunovic","year":"2014","journal-title":"Can J Ophthalmol"},{"issue":"3","key":"10.1016\/j.ajo.2026.06.035_bib0023","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1001\/jamaophthalmol.2015.5346","article-title":"Persistent macular thickening after ranibizumab treatment for diabetic macular edema with vision impairment","volume":"134","author":"Bressler","year":"2016","journal-title":"JAMA Ophthalmol"},{"issue":"3","key":"10.1016\/j.ajo.2026.06.035_bib0024","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1001\/jamaophthalmol.2017.6565","article-title":"Persistent macular thickening following intravitreous aflibercept, bevacizumab, or ranibizumab for central-involved diabetic macular edema with vision impairment: a secondary analysis of a randomized clinical trial","volume":"136","author":"Bressler","year":"2018","journal-title":"JAMA Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2026.06.035_bib0025","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1001\/jamaophthalmol.2015.4599","article-title":"Association of baseline visual acuity and retinal thickness with 1-year efficacy of aflibercept, bevacizumab, and ranibizumab for diabetic macular edema","volume":"134","author":"Wells","year":"2016","journal-title":"JAMA Ophthalmol"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939426003417?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939426003417?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T16:33:51Z","timestamp":1788280431000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939426003417"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":25,"alternative-id":["S0002939426003417"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2026.06.035","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic Response to Anti-Vascular Endothelial Growth Factor Retreatment Among Eyes With Stabilized Vision After Being Lost to Follow-Up in Diabetic Macular Edema: A Nationwide, Registry-Based Cohort Study","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2026.06.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}